Nuvo Pharmaceuticals Inc (TSE:NRI) shares hit a new 52-week low during trading on Tuesday . The company traded as low as C$1.10 and last traded at C$1.10, with a volume of 31693 shares trading hands. The stock had previously closed at C$1.20.

Separately, Bloom Burton reaffirmed a “buy” rating on shares of Nuvo Pharmaceuticals in a research report on Monday, April 1st.

The stock has a market cap of $12.50 million and a P/E ratio of -1.74. The company has a current ratio of 2.08, a quick ratio of 1.53 and a debt-to-equity ratio of 629.34.

Nuvo Pharmaceuticals (TSE:NRI) last announced its quarterly earnings data on Friday, March 29th. The specialty pharmaceutical company reported C($0.37) EPS for the quarter. The company had revenue of C$4.61 million for the quarter, compared to analysts’ expectations of C$4.50 million. As a group, sell-side analysts predict that Nuvo Pharmaceuticals Inc will post -1.34000001206 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Nuvo Pharmaceuticals (NRI) Sets New 12-Month Low at $1.10” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at

About Nuvo Pharmaceuticals (TSE:NRI)

Nuvo Pharmaceuticals Inc, a commercial healthcare company, produces and sells pharmaceutical products in the United States, Canada, and Europe. It offers Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid for the treatment of the pain of osteoarthritis of the knee; Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch that provides local analgesia prior to painful needle procedures, such as dialysis, blood draws, and pediatric needles; and Resultz, an over-the-counter product intended to kill head lice and remove their eggs from hair.

See Also: Beige Book

Receive News & Ratings for Nuvo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvo Pharmaceuticals and related companies with's FREE daily email newsletter.